It also includes:

The Zephyr Valve
The Zephyr Endobronchial Valve is an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema.

StratX Lung Analysis Platform
A cloud-based quantitative computed tomography (CT) analysis service that provides information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the Zephyr Valve treatment.

StratX Lung Analysis Platform
A cloud-based quantitative computed tomography (CT) analysis service that provides information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the Zephyr Valve treatment.

This combination of assessment tools and therapeutics enables physicians to successfully predict outcomes and provide optimal treatment for each individual patient.

Meeting an Unmet Need
COPD refers to a group of lung diseases characterized by obstruction of airflow that interferes with normal breathing.

In 2015, it affected approximately 175 million patients and was responsible for 3.2 million deaths globally.
In the United States, COPD is the third leading cause of death and affected approximately 16 million Americans as of 2013.
COPD is expected to be associated with approximately $49 billion in direct medical costs in 2020.
Emphysema, a form of COPD, is a debilitating and life-threatening disease that progressively destroys lung tissue, resulting in a diminishing ability to breathe and engage in the most basic daily activities, leading to a high mortality rate.
The lung damage caused by emphysema is irreversible.
As of 2018, approximately 3.8 million patients in the United States were diagnosed with emphysema,31 of which roughly 1.5 million have severe emphysema.

Pulmonx Investor Presentation - November 2022

Contact supplier

Stay in the loop!